 CAMBRIDGE, Mass. BEIJING HEMEL HEMPSTEAD, England--BUSINESS WIRE--BeiGene, Ltd. NASDAQ:BGNE; HKEX:06160 and EUSA Pharma UK, Ltd. today announced that the China National Medical Products Administration NMPA has granted QARZIBA dinutuximab beta conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem c 